A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
Recruiting now · Phase 1/Phase 2
Conditions studied: Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma Recurrent
In brief
This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma
Key facts
- Study ID
- NCT05417932
- Run by
- SCG Cell Therapy Pte. Ltd.
- People needed
- 46
- Starts
- 2022-10-26
- Expected to finish
- 2025-10-01
- Last updated by the study team
- 2025-02-18
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- New York — New York, New York, United States (enrolling)
- New York — New York, New York, United States (enrolling)
- Hong Kong NT — Hong Kong, Hong Kong (enrolling)
- Singapore — Singapore, Singapore (enrolling)
- Singapore — Singapore, Singapore (enrolling)
- Hong Kong is. — Hong Kong, Hong Kong
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.